239 related articles for article (PubMed ID: 34558756)
1. Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis.
Peng J; Fu M; Mei H; Zheng H; Liang G; She X; Wang Q; Liu W
Rev Med Virol; 2022 May; 32(3):e2295. PubMed ID: 34558756
[TBL] [Abstract][Full Text] [Related]
2. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19.
Khan FA; Stewart I; Fabbri L; Moss S; Robinson K; Smyth AR; Jenkins G
Thorax; 2021 Sep; 76(9):907-919. PubMed ID: 33579777
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.
de la Calle C; López-Medrano F; Pablos JL; Lora-Tamayo J; Maestro-de la Calle G; Sánchez-Fernández M; Fernández-Ruiz M; Pérez-Jacoiste Asín MA; Caro-Teller JM; García-García R; Catalán M; Martínez-López J; Sevillano Á; Origüen J; Ripoll M; San Juan R; Lalueza A; de Miguel B; Carretero O; Aguilar F; Gómez C; Paz-Artal E; Bueno H; Lumbreras C; Aguado JM
Int J Infect Dis; 2021 Apr; 105():319-325. PubMed ID: 33592340
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.
Arcani R; Correard F; Suchon P; Kaplanski G; Jean R; Cauchois R; Leprince M; Arcani V; Seguier J; De Sainte Marie B; Andre B; Koubi M; Rossi P; Gayet S; Gobin N; Garrido V; Weiland J; Jouve E; Couderc AL; Villani P; Daumas A
Front Immunol; 2023; 14():1185716. PubMed ID: 37304271
[TBL] [Abstract][Full Text] [Related]
7. Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis.
Godolphin PJ; Fisher DJ; Berry LR; Derde LPG; Diaz JV; Gordon AC; Lorenzi E; Marshall JC; Murthy S; Shankar-Hari M; Sterne JAC; Tierney JF; Vale CL
PLoS One; 2022; 17(7):e0270668. PubMed ID: 35802687
[TBL] [Abstract][Full Text] [Related]
8. The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response.
Başaran S; Şimşek-Yavuz S; Meşe S; Çağatay A; Medetalibeyoğlu A; Öncül O; Özsüt H; Ağaçfidan A; Gül A; Eraksoy H
Int J Infect Dis; 2021 Apr; 105():756-762. PubMed ID: 33737128
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis.
Yu SY; Koh DH; Choi M; Ryoo S; Huh K; Yeom JS; Yoon YK
Emerg Microbes Infect; 2022 Dec; 11(1):1154-1165. PubMed ID: 35343397
[TBL] [Abstract][Full Text] [Related]
10. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.
Cortegiani A; Ippolito M; Greco M; Granone V; Protti A; Gregoretti C; Giarratano A; Einav S; Cecconi M
Pulmonology; 2021; 27(1):52-66. PubMed ID: 32713784
[TBL] [Abstract][Full Text] [Related]
11. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.
Albuquerque AM; Eckert I; Tramujas L; Butler-Laporte G; McDonald EG; Brophy JM; Lee TC
Clin Microbiol Infect; 2023 Jan; 29(1):13-21. PubMed ID: 35863630
[TBL] [Abstract][Full Text] [Related]
12. Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis.
Dahms K; Mikolajewska A; Ansems K; Metzendorf MI; Benstoem C; Stegemann M
Eur J Med Res; 2023 Feb; 28(1):100. PubMed ID: 36841793
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis of interleulin-6 inhibitors in reducing mortality for hospitalized patients with COVID-19.
Alegre-Del-Rey EJ; Fénix-Caballero S; Salmerón-Navas FJ; Gil-Sierra MD; Sierra-Sánchez JF; Díaz-Alersi Rosety RL
Farm Hosp; 2022 May; 46(3):166-172. PubMed ID: 36183210
[TBL] [Abstract][Full Text] [Related]
14. Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic.
Mahroum N; Watad A; Bridgewood C; Mansour M; Nasr A; Hussein A; Khamisy-Farah R; Farah R; Gendelman O; Lidar M; Shoenfeld Y; Amital H; Kong JD; Wu J; Bragazzi NL; McGonagle D
Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501738
[TBL] [Abstract][Full Text] [Related]
15. Secondary Infection Risk in Patients With Severe COVID-19 Pneumonia Treated With Tocilizumab.
Sandhu G; Piraino ST; Piticaru J
Am J Ther; 2022 May-Jun 01; 29(3):e275-e278. PubMed ID: 35249968
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
17. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials.
Lin WT; Hung SH; Lai CC; Wang CY; Chen CH
Int Immunopharmacol; 2021 Jul; 96():107602. PubMed ID: 33812260
[TBL] [Abstract][Full Text] [Related]
18. Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.
Peng J; She X; Mei H; Zheng H; Fu M; Liang G; Wang Q; Liu W
Aging (Albany NY); 2022 Jan; 14(2):557-571. PubMed ID: 35038318
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.
Rezaei S; Fatemi B; Karimi Majd Z; Minaei H; Peikanpour M; Anjidani N; Taheri A; Dastan F; Mosaed R
Expert Rev Clin Immunol; 2021 May; 17(5):499-511. PubMed ID: 33823733
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K
Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
